Danaher Corporation vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while JPMorgan Diversified Return International Eqty ETF trades at $77. The key difference: Danaher Corporation pays a 0.77% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | JPIN | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | — |
52-Week High | $242.05 | $77.00 |
52-Week Low | $161.91 | $64.96 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
JPIN trades at $76.515, up 0.2% today, with technical indicators signaling a bullish trend from moving averages but caution from overbought RSI levels. The ETF, launched in 2014, provides exposure to foreign large-cap value stocks, with a dividend scheduled for June 2026. Recent news highlights its smart beta strategy and broad market category focus.
The outlook remains positive due to strong technical momentum and diversified international equity exposure, though overbought conditions and reliance on global markets pose risks. Investors benefit from value-oriented strategies but should monitor international economic volatility for potential impacts on performance.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →